EPA:IPN • FR0010259150
Overall IPN gets a fundamental rating of 6 out of 10. We evaluated IPN against 52 industry peers in the Pharmaceuticals industry. IPN has an excellent financial health rating, but there are some minor concerns on its profitability. IPN has a decent growth rate and is not valued too expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.21% | ||
| ROE | 17.93% | ||
| ROIC | 21.54% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 25.32% | ||
| PM (TTM) | 13.25% | ||
| GM | 81.66% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.19 | ||
| Debt/FCF | 1.18 | ||
| Altman-Z | 4.89 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.96 | ||
| Quick Ratio | 1.79 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.88 | ||
| Fwd PE | 13.79 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 15.92 | ||
| EV/EBITDA | 5.91 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.95% |
EPA:IPN (2/18/2026, 7:00:00 PM)
157.3
+1.7 (+1.09%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.95% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.88 | ||
| Fwd PE | 13.79 | ||
| P/S | 2.25 | ||
| P/FCF | 15.92 | ||
| P/OCF | 11.4 | ||
| P/B | 3.04 | ||
| P/tB | 9.32 | ||
| EV/EBITDA | 5.91 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.21% | ||
| ROE | 17.93% | ||
| ROCE | 27.02% | ||
| ROIC | 21.54% | ||
| ROICexc | 29.88% | ||
| ROICexgc | 113.42% | ||
| OM | 25.32% | ||
| PM (TTM) | 13.25% | ||
| GM | 81.66% | ||
| FCFM | 14.11% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.19 | ||
| Debt/FCF | 1.18 | ||
| Debt/EBITDA | 0.4 | ||
| Cap/Depr | 52.58% | ||
| Cap/Sales | 5.6% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 54.79% | ||
| Profit Quality | 106.48% | ||
| Current Ratio | 1.96 | ||
| Quick Ratio | 1.79 | ||
| Altman-Z | 4.89 |
ChartMill assigns a fundamental rating of 6 / 10 to IPN.PA.
ChartMill assigns a valuation rating of 5 / 10 to IPSEN (IPN.PA). This can be considered as Fairly Valued.
IPSEN (IPN.PA) has a profitability rating of 6 / 10.
The financial health rating of IPSEN (IPN.PA) is 7 / 10.
The dividend rating of IPSEN (IPN.PA) is 3 / 10 and the dividend payout ratio is 14.95%.